Licensing : nature.com subject feedshttps://www.nature.com/subjects/licensing.atom2024-03-28T11:46:26+00:00Galderma pursues 'itchy cytokine' by licensing antibody from Roche's Chugaihttps://www.nature.com/articles/nrd.2016.1652016-08-30T00:00:00+00:002016-08-30T00:00:00+00:00Megan CullyMSD buys in to emerging epigenetic cancer targethttps://www.nature.com/articles/nrd.2016.202016-03-02T00:00:00+00:002016-03-02T00:00:00+00:00Megan CullyKeeping score, strengthening policy and fighting bad actors over access to research toolshttps://www.nature.com/articles/nbt.31312015-02-06T00:00:00+00:002015-02-06T00:00:00+00:00Tania Bubela et al.FDA OKs breakthrough B meningitis vaccinehttps://www.nature.com/articles/nbt0115-9a2015-01-09T00:00:00+00:002015-01-09T00:00:00+00:00Reinventing tech transferhttps://www.nature.com/articles/nbt.30852014-12-09T00:00:00+00:002014-12-09T00:00:00+00:00Brady HuggettThe premium of a big pharma license dealhttps://www.nature.com/articles/nbt.29462014-07-08T00:00:00+00:002014-07-08T00:00:00+00:00Kara E O'Connell et al.Better than breakthrough scheme snagshttps://www.nature.com/articles/nbt0514-403b2014-05-08T00:00:00+00:002014-05-08T00:00:00+00:00Nuala MoranAnthrax drug first antibacterial mAb to win approvalhttps://www.nature.com/articles/nbt0113-82013-01-09T00:00:00+00:002013-01-09T00:00:00+00:00Jeffrey L FoxCompulsory license bandwagon gains momentumhttps://www.nature.com/articles/nbt0912-814a2012-09-10T00:00:00+00:002012-09-10T00:00:00+00:00Michael FranciscoGSK buys partner Human Genome Scienceshttps://www.nature.com/articles/nbt0912-815a2012-09-10T00:00:00+00:002012-09-10T00:00:00+00:00Mark RatnerThe time for pharmaceutical compulsory licensing has expiredhttps://www.nature.com/articles/nm0812-11682012-08-06T00:00:00+00:002012-08-06T00:00:00+00:00Randall Kuhn et al.Erratum: In Their Wordshttps://www.nature.com/articles/nbt0612-562d2012-06-07T00:00:00+00:002012-06-07T00:00:00+00:00Monsanto to face biopiracy charges in Indiahttps://www.nature.com/articles/nbt0112-112012-01-09T00:00:00+00:002012-01-09T00:00:00+00:00Lucas LaursenCorrectionhttps://www.nature.com/articles/nm0112-7b2012-01-06T00:00:00+00:002012-01-06T00:00:00+00:00China eyes Western biologicshttps://www.nature.com/articles/nbt1111-960b2011-11-08T00:00:00+00:002011-11-08T00:00:00+00:00Hepeng JiaStanford program gives discoveries a shot at commercializationhttps://www.nature.com/articles/nm1111-1326b2011-11-07T00:00:00+00:002011-11-07T00:00:00+00:00Mike MayPharmaceutical patent evaluation and licensing using a stochastic model and Monte Carlo simulationshttps://www.nature.com/articles/nbt.19632011-09-08T00:00:00+00:002011-09-08T00:00:00+00:00Liangchuan Wu et al.French law to make conflict of interest disclosure mandatoryhttps://www.nature.com/articles/nm0911-1026a2011-09-07T00:00:00+00:002011-09-07T00:00:00+00:00Sabine LouëtBridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug responsehttps://www.nature.com/articles/nrd35012011-07-01T00:00:00+00:002011-07-01T00:00:00+00:00Hans-Georg Eichler et al.Disputed EU herbal medicine rules take forcehttps://www.nature.com/articles/nm0611-636b2011-06-06T00:00:00+00:002011-06-06T00:00:00+00:00Karen DentePartnering Brazilian biotech with the global pharmaceutical industryhttps://www.nature.com/articles/nbt.18012011-03-09T00:00:00+00:002011-03-09T00:00:00+00:00Luiz A B de CastroLicence rules hinder work on rare diseasehttps://www.nature.com/articles/470318a2011-02-16T00:00:00+00:002011-02-16T00:00:00+00:00Erika Check Hayden Co-promotion deals: panacea or poison pill?https://www.nature.com/articles/nrd33102010-10-29T00:00:00+00:002010-10-29T00:00:00+00:00Nigel Borshell et al.GSK's RNA splashhttps://www.nature.com/articles/nbt0610-539b2010-06-01T00:00:00+00:002010-06-01T00:00:00+00:00Janelle Weaver Novartis licenses GenVec's hearing loss programmehttps://www.nature.com/articles/nrd31262010-03-01T00:00:00+00:002010-03-01T00:00:00+00:00 Trends in discovery externalizationhttps://www.nature.com/articles/nrd31282010-03-01T00:00:00+00:002010-03-01T00:00:00+00:00Stephen MayhewRelative efficacy of drugs: an emerging issue between regulatory agencies and third-party payershttps://www.nature.com/articles/nrd30792010-02-26T00:00:00+00:002010-02-26T00:00:00+00:00Hans-Georg Eichler et al. Dipping into Incyte's JAK-pothttps://www.nature.com/articles/nrd31132010-02-01T00:00:00+00:002010-02-01T00:00:00+00:00